Aspen’s share price dips on news of R719m drug writedown
Australian regulators order the recall of heartburn, acid reflux and ulcer medicine Zantac due to possible cancer risks
29 October 2019 - 07:28
Africa’s largest drug company, Aspen Pharmacare, has written down the value of a heartburn medicine it sells primarily in Australia by R719m after it was recalled due to possible cancer risks.
The company’s full-year results to end-June have been restated on a “worst-case basis” after Australian regulators ordered the recall of all products containing ranitidine, which contains a by-product that may pose a low carcinogenic risk from long-time exposure...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.